NCT04557098 (MajesTEC-1) is a Phase 2 clinical trial of Teclistamab in Hematological Malignancies, sponsored by Janssen Research & Development, LLC.

Who is sponsoring NCT04557098?

NCT04557098 is sponsored by Janssen Research & Development, LLC.

What drugs are being tested in NCT04557098?

Interventions in NCT04557098: Teclistamab.

What condition does NCT04557098 study?

NCT04557098 studies Hematological Malignancies.

Is NCT04557098 still recruiting?

NCT04557098 is currently active, enrolled. Last updated 13 April 2026.

Last reviewed 2026-04-13 · How we verify

NCT04557098: MajesTEC-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Active, enrolled Phase 2 Last updated 13 April 2026

What this trial tests

Phase 2 trial testing Teclistamab in Hematological Malignancies in 194 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

17 September 2020

Primary endpoint
9 November 2021

28 May 2027

Quick facts

Lead sponsor	Janssen Research & Development, LLC
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	194
Start date	17 September 2020
Primary completion	9 November 2021
Estimated completion	28 May 2027
Sites	51 locations across France, Italy, Netherlands, Belgium, Sweden, United Kingdom, Germany, Canada

Drugs / interventions tested

Teclistamab (TECLISTAMAB) — full drug profile →

Conditions studied

Hematological Malignancies — all drugs for Hematological Malignancies →

Sponsor

Janssen Research & Development, LLC — full company profile →

Who can join

18 and older, any sex, with Hematological Malignancies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Teclistamab in Relapsed or Refractory Multiple Myeloma.
Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, et al · · 2022 · cited 847× · PMID 35661166 · DOI 10.1056/nejmoa2203478
Emerging new therapeutic antibody derivatives for cancer treatment.
Jin S, Sun Y, Liang X, Gu X, et al · · 2022 · cited 304× · PMID 35132063 · DOI 10.1038/s41392-021-00868-x
Antibodies to watch in 2022.
Kaplon H, Chenoweth A, Crescioli S, Reichert JM. · · 2022 · cited 245× · PMID 35030985 · DOI 10.1080/19420862.2021.2014296
Antibodies to watch in 2023.
Kaplon H, Crescioli S, Chenoweth A, Visweswaraiah J, et al · · 2023 · cited 204× · PMID 36472472 · DOI 10.1080/19420862.2022.2153410
Current landscape and future directions of bispecific antibodies in cancer immunotherapy.
Wei J, Yang Y, Wang G, Liu M. · · 2022 · cited 127× · PMID 36389699 · DOI 10.3389/fimmu.2022.1035276
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel.
Raje N, Anderson K, Einsele H, Efebera Y, et al · · 2023 · cited 120× · PMID 37528088 · DOI 10.1038/s41408-023-00879-7
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
Tapia-Galisteo A, Álvarez-Vallina L, Sanz L. · · 2023 · cited 87× · PMID 37501154 · DOI 10.1186/s13045-023-01482-w
Bispecific Antibodies in Multiple Myeloma: Present and Future.
Lancman G, Sastow DL, Cho HJ, Jagannath S, et al · · 2021 · cited 75× · PMID 34661161 · DOI 10.1158/2643-3230.bcd-21-0028

Verify or expand the search:

Other trials of Teclistamab

Trials testing the same drug.

NCT07463807 — Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carf · Phase 1, PHASE2 · not yet recruiting
NCT07518186 — A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · Phase 3 · not yet recruiting
NCT07332507 — Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma · Phase 1 · not yet recruiting
NCT06948084 — Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Darat · Phase 2 · not yet recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other recruiting trials for Hematological Malignancies

Currently open trials in the same condition.

NCT07220616 — A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies · Phase 1, PHASE2 · recruiting
NCT06584955 — Feasibility of the Use of Weighted Blankets to Improve Sleep Among Patients With Hematological Malignancies · NA · active not recruiting
NCT06387082 — A Clinical Study of HMPL-506 in Patients With Hematological Malignancies · Phase 1 · recruiting
NCT06150469 — Efficacy of Inhaled Aromatherapy on Nausea and Vomiting in Hematological Malignancies · NA · recruiting
NCT06179511 — Study of AZD9829 in CD123+ Hematological Malignancies · Phase 1, PHASE2 · active not recruiting

Other Janssen Research & Development, LLC trials

Trials by the same sponsor.

NCT07518186 — A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · Phase 3 · not yet recruiting
NCT07309445 — A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC · recruiting
NCT07499232 — A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease · Phase 3 · not yet recruiting
NCT07438496 — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus · Phase 3 · recruiting
NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04557098 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Research & Development, LLC
Last refreshed: 13 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04557098.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing